Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3597 - MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours


08 Oct 2016


Poster Display


Richard Wilson


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


R. Wilson1, M.R. Middleton2, J. Houlden2, S. Van Schaeybroeck3, C.D. Rolfo4, E. Elez5, J. Taieb6, T. André7, A. Bardelli8, P. Laurent-Puig9, J. Tabernero10, M. Peeters11, T. Maughan2, C. Roberts2, S. Love2, M. Lawler12, M. Salto-Tellez12, M. Grayson13, V. Popovici14, F. Di Nicolantonio8

Author affiliations

  • 1 Centre For Cancer Research And Cell Biology, Belfast City Hospital Northern Ireland Cancer Centre, School of Medicine, Dentistry & Biomedical Science, BT9 7AE - Belfast/GB
  • 2 Oncology Clinical Trials Office (octo), Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford/GB
  • 3 Oncology, Belfast City Hospital Northern Ireland Cancer Centre, School of Medicine, Dentistry & Biomedical Science, BT9 7AE - Belfast/GB
  • 4 Phase I - Early Clinical Trials Unit & Center For Oncological Research Of Antwerp (core), Antwerp University Hospital, 2650 - Edegem/BE
  • 5 Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08015 - Barcelona/ES
  • 6 Gastroenterology And Digestive Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 7 Oncologie Médicale, Hopital St. Antoine, 75571 - Paris/FR
  • 8 Dept Of Oncology, IRCCs University of Torino School of Medicine, 10060 - Candiolo/IT
  • 9 Department Of Biology, Hopital European George Pompidou, Paris/FR
  • 10 Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 11 Department Of Oncology, University Hospital Antwerp, 2650 - Edegem/BE
  • 12 Centre For Cancer Research And Cell Biology, Queen's University Belfast, Belfast/GB
  • 13 Ni Cancer Trials Network, Belfast City Hospital Northern Ireland Cancer Centre, School of Medicine, Dentistry & Biomedical Science, Belfast/GB
  • 14 Institute Of Biostatistics, Masaryk University Faculty of Medicine, Brno/CZ


Abstract 3597


RAS activating mutations occur in ∼55% of metastatic (m) CRC. RASMT and >50% of RASWT mCRC patients (pts) do not benefit from anti-EGFR antibodies. c-MET is overexpressed in ∼50-60%, amplified in ∼2-3% and mutated in ∼1-3% of mCRC. Preclinical data support the clinical evaluation of MEK1/2 and METi, in particular in RASMT tumours and RASWT with aberrant c-MET expression. The primary aim of the phase I study was to establish the maximum tolerated dose (MTD) and assess safety/toxicity profile of PD-0325901 MEKi & crizotinib METi in pts with advanced solid tumours using NCI CTCAE V4.03.


A single arm, open-label phase I trial of PD-0325901 with crizotinib was performed in pts with advanced solid tumours, measurable disease, ECOG PS 0-1 and adequate end organ function. Pts received oral PD-0325901 BD (days 1-21 every 28 days) at doses of 2 - 8mg BD with oral crizotinib continuously at 250mg OD or 200mg BD, using a rolling 6 design. Crizotinib started after a 1 week lead-in with PD-0325901. Blood samples for pharmacokinetics, pERK and soluble c-MET levels and skin biopsies for pERK levels were collected.


Between 12/2014 and 11/2015 we enrolled 25 pts; Male (13), Female (12). Median age 63 yrs (range 36-78). MTD was defined at the highest dose; crizotinib: 200mg BD continuously; PD-0325901: 8mg BD days 1-21 every 28 days. 1 of 6 patients exhibited dose-limiting toxicity (fatigue) at this dose level. The 25 pts received a total of 52 cycles. Drug-related adverse events were in keeping with single agent toxicity profiles, including rash, diarrhoea, fatigue, nausea, hypoalbuminemia and visual disturbances. Best clinical response was stable disease at the end of cycle 2, in 4/25 evaluable pts.


MEK/METi can be given together at pharmacologically active doses. MTD for the PD-0325901/crizotinib combination was 8mg BD (days 1-21) and 200mg BD continuously in a 28 day cycle. The combination is now being explored further with an alternate MEKi before expansion into RASMT and RASWT CRC with aberrant c-MET expression. EudraCT registry number: 2014-000463-40.

Clinical trial identification

EudraCT Number: 2014-000463-40

Legal entity responsible for the study

University of Oxford


European FP7 Grant


M.R. Middleton: Consultant: Amgen, AZ, BMS, Eisai, GSK, Lilly, Merck, Millenium, Novartis, Physiomics, Rigontec, Roche Grant/Research support: Abbvie, Amgen, AZ, BMS, Clovis, Eisai, GSK, Immunocore, Merck, Millenium, Novartis, Pfizer, Roche, Vertex (all to institution). J. Tabernero: Consultant/Advisory role: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Merck Serono, Novartis, Roche, Sanofi, Symphogen, Takeda and Taiho. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings